Luxdegalutamide

3 trials 2 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

1 Completed trials

1 Sponsors

9 Countries

Phase II

Phase I/II

Phase II: 2 Phase I/II: 1

Oversight events:

2 unexpected events across 1 trial

View oversight register →

Sponsors using this IMP

Novartis Pharma AG 3

All trials

3 total

A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon… Recruiting

2025-521880-10-00 Phase I/II 6 countries Novartis Pharma AG
An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Phase II 7 countries Novartis Pharma AG
A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxeta… Ended

2024-520155-24-00 Phase II 7 countries Novartis Pharma AG

Showing 1–3 of 3 trials

← All drugs A–Z